Skip to main content

Advertisement

SpringerLink
Log in

Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies

  • Geriatric Disorders (W McDonald, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

This update on Alzheimer’s disease (AD) discusses treatment strategies for cognitive and neuropsychiatric symptoms (such as agitation, psychosis, anxiety, and depression) common in this illness, emphasizing in particular nonpharmacologic strategies such as cognitive interventions, physical exercise, and psychotherapy. We provide an overview of cognitive enhancers and their combination strategies and medications commonly used for treatment of neuropsychiatric symptoms in AD. Finally, we give recommendations for providing support to caregivers and suggest how to identify caregiver/patient pairs most in need of intensive dementia care services.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Alzheimer’s Association. Alzheimer’s Association Report: 2013 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2013;9:208-245.

  2. Reitz C, Mayeux R. Alzheimer’s disease: epidemiology, diagnostic criteria, risk factors, and biomarkers. Biochem Pharmacol. 2014;88:640–51.

    Article  CAS  PubMed  Google Scholar 

  3. Galimberti D, Scarpini E. Progress in Alzheimer’s disease research in the last year. J Neurol. 2013;260:1936–41.

    Article  PubMed  Google Scholar 

  4. DeFina PA, Moser RS, Glenn M, et al. Alzheimer’s Disease clinical and research update for health care practitioners. J Aging Res. 2013;2013:207178. doi:10.1155/2013/207178.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review. J Alzheimer’s Dis. 2014;41:615–31.

    CAS  Google Scholar 

  6. Hernandez RK, Farwell D, Kantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc. 2009;57:1997–2003.

    Article  PubMed  Google Scholar 

  7. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36:375–99.

    Article  CAS  PubMed  Google Scholar 

  8. Pepeu G, Giovanni MG, Braco L. Effect of cholinesterase inhibitors on attention. Chem Biol Interact. 2013;203:361–4.

    Article  CAS  PubMed  Google Scholar 

  9. Ferris SH, Farlow M. Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging. 2013;8:1007–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer disease. Neurotox Res. 2013;24:358–69.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9:338–45. An excellent summary of the duration and degree of benefit provided by the antidementia drugs and recommendations on their use as monotherapy and in combination.

    Article  PubMed  Google Scholar 

  12. Di Santo SG, Prinelli F, Adorni F, et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to the severity of Alzheimer’s disease. J Alzheimer’s Dis. 2013;35:349–61.

    Google Scholar 

  13. Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol. 2011;11:57–65.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2:e000917. doi:10.1136/bmjopen-2012-000917.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9:326–31.

    Article  PubMed  Google Scholar 

  16. Shah R. The role of nutrition and diet in Alzheimer disease: a systematic review. J Am Med Dir Assoc. 2013;14:398–402. A wonderful summary of current evidence regarding the impact of nutritional supplements and dietary modifications on cognitive decline in AD.

    Article  PubMed  Google Scholar 

  17. Forbes D, Thiessen EJ, Blake CM, et al. Exercise programs for people with dementia (Review). Cochrane Database Syst Rev. 2013;12, CD006489. A much-needed plain-language summary of the potential benefits of exercise in dementia, an update on the Cochrane review from 2008.

    PubMed  Google Scholar 

  18. Pitkälä K, Savikko N, Poysti M, et al. Efficacy of physical exercise intervention on mobility and physical functioning in older people with dementia: a systematic review. Exp Gerontol. 2013;48:85–93.

    Article  PubMed  Google Scholar 

  19. Blankevoort CG, Van Heuvelen MJG, Boersma F, et al. Review of effects of physical activity on strength, balance, mobility and ADL performance in elderly subjects with dementia. Dement Geriatr Cogn Disord. 2010;30:392–402.

    Article  PubMed  Google Scholar 

  20. Alves J, Magalhaes R, Thomas RE, et al. Is there evidence for cognitive intervention in Alzheimer disease? A systematic review of efficacy, feasibility, and cost-effectiveness. Alzheimer Dis Assoc Disord. 2013;27:195–203. A very selective review of only high-quality RCTs of cognitive interventions in AD, calling for further much-needed well-designed research in this area.

    Article  PubMed  Google Scholar 

  21. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer’s or vascular ype: a review. Alzheimer’s Res Ther. 2013;5:35.

    Google Scholar 

  22. Shecker M, Pirnay-Dummer P, Schmidtke K, et al. Cognitive Interventions in mild Alzheimer’s Disease: a therapy-evaluation study on the interaction of medication and cognitive treatment. Dement Geriatr Cogn Disord. 2013;3:301–11.

    Article  Google Scholar 

  23. Kannan SF, McDowd JM, Colgrove Y, et al. Feasibility and efficacy of intensive cognitive training in early-stage Alzheimer’s disease. Am J Alzheimers Dis Other Dement. 2014;29:150–8.

    Article  Google Scholar 

  24. Ballard C, Khan Z, Clack H, Corbett A. Non-pharmacologic treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):589–95.

    PubMed  Google Scholar 

  25. Buschert V, Bokde ALW, Hampel H. Cognitive intervention in Alzheimer disease. Nat Rev Neurol. 2010;6:508–17.

    CAS  PubMed  Google Scholar 

  26. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr. 2010;22(3):346–72. An excellent review of treatment of neuropsychiatric symptoms in AD.

    Article  PubMed  Google Scholar 

  27. Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–81.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;277(10):806–12.

    Article  CAS  PubMed  Google Scholar 

  29. A. P. A. Work Group on Alzheimer's disease and other dementias, Rabins PV, Blacker D, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12 Suppl):5–56.

    PubMed  Google Scholar 

  30. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006;14(7):561–72.

    Article  PubMed  Google Scholar 

  31. Ballard CG, Margallo-Lana M, Fossey J, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry. 2001;62(8):631–6.

    Article  CAS  PubMed  Google Scholar 

  32. American Psychiatric Association and American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association. xliv; 2013. p. 947. xliv, 947 p.

    Google Scholar 

  33. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc. 1994;42(11):1160–6.

    CAS  PubMed  Google Scholar 

  34. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9(4):361–81.

    Article  CAS  PubMed  Google Scholar 

  35. Sloane PD, Hoeffer B, Mitchell CM, et al. Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: a randomized, controlled trial. J Am Geriatr Soc. 2004;52:1795–804.

    Article  PubMed  Google Scholar 

  36. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20(5):459–64.

    Article  CAS  PubMed  Google Scholar 

  37. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5):813–24.

    Article  PubMed  Google Scholar 

  38. Grossberg GT, Pejovic V, Miller ML, et al. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;27(2):164–72.

    Article  CAS  PubMed  Google Scholar 

  39. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60(2):107–15.

    Article  CAS  PubMed  Google Scholar 

  40. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968–76.

    Article  CAS  PubMed  Google Scholar 

  41. Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(7):537–50.

    Article  PubMed  Google Scholar 

  42. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007;4(1):81–93.

    Article  CAS  PubMed  Google Scholar 

  43. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525–38.

    Article  CAS  PubMed  Google Scholar 

  44. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.

    Article  CAS  PubMed  Google Scholar 

  45. Kamble P, Chen H, Sherer JT, et al. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging. 2009;26(6):483–92.

    Article  PubMed  Google Scholar 

  46. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA. 2014;311(7):682–91. An important RCT of citalopram for agitation in dementia associated with AD.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19(1):23–8.

    Article  CAS  PubMed  Google Scholar 

  48. Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744–51.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Ujkaj M, Davidoff DA, Seiner SJ, et al. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry. 2012;20:61–72. The largest examination of ECT for agitation in demented patients.

    Article  PubMed  Google Scholar 

  50. Starkstein SE, Chemerinski E, Sabe L, et al. Prospective longitudinal study of depression and anosognosia in Alzheimer's disease. Br J Psychiatry. 1997;171:47–52.

    Article  CAS  PubMed  Google Scholar 

  51. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Teng E, Ringman JM, Ross LK, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008;16(6):469–77.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Van der Mussele S, Bekelaar K, Le Bastard N, et al. Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. Int J Geriatr Psychiatry. 2013;28(9):947–58.

    Article  PubMed  Google Scholar 

  54. Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. Neurology. 1998;51(1 Suppl 1):S53–60. discussion S5-7.

    Article  CAS  PubMed  Google Scholar 

  55. Garcia-Alberca JM, Lara JP, et al. Sleep disturbances in Alzheimer's disease are associated with neuropsychiatric symptoms and antidementia treatment. J Nerv Ment Dis. 2013;201(3):251–7.

    Article  PubMed  Google Scholar 

  56. Porta-Etessam J, Tobaruela-Gonzalez JL, Rabes-Berendes C. Depression in patients with moderate Alzheimer disease: a prospective observational cohort study. Alzheimer Dis Assoc Disord. 2011;25(4):317–25.

    Article  CAS  PubMed  Google Scholar 

  57. Seyfried LS, Kales HC, Ignacio RV, et al. Predictors of suicide in patients with dementia. Alzheimers Dement. 2011;7(6):567–73.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Kritz-Silverstein D, Barrett-Connor E, Corbeau C. Cross-sectional and prospective study of exercise and depressed mood in the elderly: the Rancho Bernardo study. Am J Epidemiol. 2001;153(6):596–603.

    Article  CAS  PubMed  Google Scholar 

  59. Vital TM, Hernandez SS, Stein AM, et al. Depressive symptoms and level of physical activity in patients with Alzheimer's disease. Geriatr Gerontol Int. 2012;12(4):637–42.

    Article  PubMed  Google Scholar 

  60. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003;290(15):2015–22.

    Article  CAS  PubMed  Google Scholar 

  61. Sturmey P. Behavioral activation is an evidence-based treatment for depression. Behav Modif. 2009;33(6):818–29.

    Article  PubMed  Google Scholar 

  62. Regan B, Varanelli L. Adjustment, depression, and anxiety in mild cognitive impairment and early dementia: a systematic review of psychological intervention studies. Int Psychogeriatr. 2013;25(12):1963–84.

    Article  PubMed  Google Scholar 

  63. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577–85.

    Article  PubMed  Google Scholar 

  64. Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136–45.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18(4):332–40.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–11. A recent well-designed trial of antidepressants for treatment of depression in dementia, with negative results.

    Article  CAS  PubMed  Google Scholar 

  67. Echavarri C, Burgmans S, Uylings H, et al. Neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013;33(3):715–21.

    PubMed  Google Scholar 

  68. Teri L, Ferretti LE, Gibbons LE, et al. Anxiety of Alzheimer's disease: prevalence, and comorbidity. J Gerontol A Biol Sci Med Sci. 1999;54(7):M348–52.

    Article  CAS  PubMed  Google Scholar 

  69. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001;13(2):233–40.

    Article  CAS  PubMed  Google Scholar 

  70. Starkstein SE, Jorge R, Petracca G, et al. The construct of generalized anxiety disorder in Alzheimer disease. Am J Geriatr Psychiatry. 2007;15(1):42–9.

    Article  PubMed  Google Scholar 

  71. Ferretti L, McCurry SM, Logsdon R, et al. Anxiety and Alzheimer's disease. J Geriatr Psychiatry Neurol. 2001;14(1):52–8.

    Article  CAS  PubMed  Google Scholar 

  72. Hynninen MJ, Breitve MH, Rongve A, et al. The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. Int Psychogeriatr. 2012;24(11):1771–8.

    Article  PubMed  Google Scholar 

  73. Gibbons L, Teri L, Logsdon R, et al. Anxiety symptoms as predictors of nursing home placement in patients with Alzheimer's disease. J Clin Geropsych. 2002;8(4):335–42.

    Article  Google Scholar 

  74. Paukert AL, Calleo J, Kraus-Schuman C, et al. Peaceful Mind: an open trial of cognitive-behavioral therapy for anxiety in persons with dementia. Int Psychogeriatr. 2010;22(6):1012–21.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Qazi A, Spector A, Orrell M. User, carer and staff perspectives on anxiety in dementia: a qualitative study. J Affect Disord. 2010;125(1–3):295–300.

    Article  PubMed  Google Scholar 

  76. Gardner ME, Malone DC, Sey M, et al. Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. J Am Med Dir Assoc. 2004;5(2):101–6.

    Article  PubMed  Google Scholar 

  77. Savaskan E, Schnitzler C, Schroder C, et al. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol. 2006;9(5):507–16.

    Article  CAS  PubMed  Google Scholar 

  78. Cooper JP. Buspirone for anxiety and agitation in dementia. J Psychiatry Neurosci. 2003;28(6):469.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Beinart N, Weinman J, Wade D, Brady R. Caregiver burden and psychoeducational interventions in Alzheimer’s disease: a review. Dement Geriatr Cogn Dis Extra. 2012;2:638–48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. US Department of Health and Human Services. National plan to address Alzheimer’s disease: 2014 update.

  81. Levy K, Lanctot KL, Farber SB, et al. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease relieve caregiver burden? Drugs Aging. 2012;29(3):167–79.

    Article  CAS  PubMed  Google Scholar 

  82. Vann AS. A caregiver’s wish list for a national Alzheimer’s agenda. Am J Alzheimers Dis Other Dement. 2014;29(2):111–3. A wish list from a caregiver – an important perspective for anyone involved in the treatment of patients with dementia.

    Article  Google Scholar 

  83. Zabalegui A, Hamers JPH, Karlsson S, et al. Best practices interventions to improve quality of care of people with dementia living at home. Patient Educ Couns. 2014;95:175–84.

    Article  PubMed  Google Scholar 

  84. Bass DM, Judge KS, Snow AL, et al. Caregiver outcomes of Partners in Dementia Care: effect of a care coordination program for veterans with dementia and their family members and friends. J Am Geriatr Soc. 2013;61:1377–86. Description of a model program meant to enhance care provision for patients with AD and their caregivers.

    Article  PubMed  Google Scholar 

  85. Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med. 2006;145:713–26.

    Article  PubMed  Google Scholar 

  86. Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;295:2148–57.

    Article  CAS  PubMed  Google Scholar 

  87. Passoni S, Moroni L, Toraldo A, et al. Cognitive behavioral group intervention for Alzheimer caregivers. Alzheimer Dis Assoc Disord. 2014. doi:10.1097/WAD.0000000000000033.

  88. Godwin KM, Millis WL, Anderson JA. Kunik ME Technology-driven interventions for caregivers of persons with dementia: a systematic review. Am J Alzheimers Dis Other Dement. 2013;28:216–22.

    Article  Google Scholar 

  89. Lines LM, Ahaghoute C, Tilly J, Wiener JM. Care coordination for people with Alzheimer’s disease and related dementias: literature review. US Department of Health and Human Services Assistant Secretary for Planning and Evaluation Office of Disability, Aging, and Long-Term Care Policy. December 2013.

  90. Lessig M, Farrell J, Madhavan E, et al. Cooperative dementia care clinics: a new model for managing cognitively impaired patients. J Am Geriatr Soc. 2006;54:1937–42.

    Article  PubMed  Google Scholar 

  91. Borson S, Scanlan JM, Sadak T, et al. The Dementia Services Mini-Screen: a simple method to identify patients and caregivers needing enhanced dementia care services. Am J Geriatr Psychiatry. 2013. doi:10.1016/j.jagp.2013.11.001. (Epub ahead of print). A helpful guide to identify patients and caregivers who need higher level of services.

    PubMed  Google Scholar 

  92. Borson S, Chodosh J. Developing dementia-capable health care systems: a 12-step program. Clin Geriatric Med: Update in Geriatric Psychiatry (in press).

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Anna Borisovskaya, Marcella Pascualy, and Soo Borson declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. VA Puget Sound Healthcare System, Department of Psychiatry and Behavioral Sciences, University of Washington, 1660 S. Columbian Way, S-116, Seattle, WA, 98108, USA

    Anna Borisovskaya & Marcella Pascualy

  2. Department of Psychiatry and Behavioral Sciences (Emerita), University of Washington, 2375 S Toledo Avenue, Palm Springs, CA, 92264, USA

    Soo Borson

Authors
  1. Anna Borisovskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcella Pascualy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soo Borson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soo Borson.

Additional information

This article is part of the Topical Collection on Geriatric Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Borisovskaya, A., Pascualy, M. & Borson, S. Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies. Curr Psychiatry Rep 16, 470 (2014). https://doi.org/10.1007/s11920-014-0470-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-014-0470-z

Keywords

Search

Navigation